Newsroom and Events
Press releases
Amlogenyx to Present at the Wells Fargo 21st Annual Healthcare Conference
NOVATO, Calif., September 2, 2026 – Amlogenyx, Inc., a biotechnology company focused on developing gene therapies for Alzheimer’s disease and other neurodegenerative diseases, today announced members of the Company management team will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, Mass., on Tuesday, September 8, 2026, at 3:00 PM ET.
Read more
Amlogenyx Presents Preclinical Data on AM805, a Potentially Transformative Investigational Gene Therapy for Alzheimer’s Disease
A novel approach using a lysosomal enzyme to prevent and reverse amyloid accumulation inside as well as outside neurons, with greater potency, delivered in a one-time gene therapy.
Read moreAmlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques with the potential to be superior to monoclonal antibodies and restore neuronal function while halting or reversing disease progression.
Read moreAmlogenyx Announces Expansion of Board of Directors and Formation of Scientific Advisory Board
Advancing a novel gene therapy to treat Alzheimer’s disease. Appointed three Alzheimer’s experts to newly formed Scientific Advisory Board. Gene therapy expertise enhanced on the board of directors with a new Independent member.
Read more